免疫检查点阻断增强225Ac-PSMA617在前列腺癌小鼠模型中的疗效
该研究在C57BL/6小鼠的同系RM1-PGLS前列腺癌模型中,比较225Ac-PSMA617、抗PD-1抗体单用或联用的疗效。结果显示联合治疗较任一单药显著延长至进展时间和生存期,提示PSMA靶向放射性核素治疗与PD-1阻断具有协同作用。
要点
- 抗PD-1单药较同型对照显著延长TTP(33.5天 vs 25天,P=0.0153)和生存期(37天 vs 28天,P=0.0098)。
- 225Ac-PSMA617单药较对照呈延长趋势但未达统计学显著(TTP P=0.1038;生存期P=0.1018)。
- 联合治疗较任一单药显著改善疾病控制,TTP达47.5天、生存期达51.5天。
核心结论
- 在前列腺癌小鼠模型中,PSMA靶向放射性核素治疗与PD-1阻断联合可协同改善治疗结局。
研究设计与样本
- 研究为小鼠前列腺癌模型研究,使用荷同系RM1-PGLS肿瘤的C57BL/6小鼠。
- 小鼠分别接受225Ac-PSMA617、抗PD-1抗体或两者联合治疗。
- 疗效通过CT肿瘤体积测量、至进展时间和生存期评估。
主要发现
- 抗PD-1单药较同型对照显著延长TTP(33.5天 vs 25天,P=0.0153)和生存期(37天 vs 28天,P=0.0098)。
- 225Ac-PSMA617单药较同型对照呈延长趋势但未达统计学显著(TTP 30天,P=0.1038;生存期32天,P=0.1018)。
- 联合治疗TTP延长至47.5天,较两种单药均有显著差异(P≤0.0199)。
- 联合治疗生存期延长至51.5天,较两种单药均有显著差异(P≤0.0251)。
临床怎么用
- 该结果为前列腺癌患者中评估放射性核素治疗与免疫治疗联合方案提供了临床前依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (RNT) may increase tumor immunogenicity. We aimed at exploiting this effect by combining RNT with immunotherapy in a mouse model of prostate cancer (PC). Methods: C57BL/6-mice bearing syngeneic RM1-PGLS tumors were treated with 225Ac-PSMA617, an anti-PD-1 antibody, or both. Therapeutic efficacy was assessed by tumor volume measurements (CT), time to progression (TTP), and survival. Results: PSMA RNT or anti-PD-1 alone tended to prolong TTP (isotype control, 25 d; anti-PD-1, 33.5 d [P = 0.0153]; RNT, 30 d [P = 0.1038]) and survival (control, 28 d; anti-PD-1, 37 d [P = 0.0098]; RNT, 32 d [P = 0.1018]). Combining PSMA RNT and anti-PD-1 significantly improved disease control compared with either monotherapy. TTP was extended to 47.5 d (P ≤ 0.0199 vs. monotherapies), and survival to 51.5 d (P ≤ 0.0251 vs. monotherapies). Conclusion: PSMA RNT and PD-1 blockade synergistically improve therapeutic outcomes in our PC model, supporting the evaluation of RNT and immunotherapy combinations for PC patients.
引用
- Czernin J, Current K, Mona CE, et al. Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer. J Nucl Med. 2020. PMID: 32646877. doi:10.2967/jnumed.120.246041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。